Home > Newsletters > FDAnews Drug Daily Bulletin > International Drug Industry Wants All Phase III Results Published
FDAnews Drug Daily Bulletin
July 7, 2010 | Vol. 7 No. 131
International Drug Industry Wants All Phase III Results Published
The international pharmaceutical industry is calling for the results of all industry-sponsored Phase III studies and those of significant medical importance to be submitted for publication in peer-reviewed journals. A joint position, adopted by the International Federation of Pharmaceutical Manufacturers and Associations, recommends that manuscripts of the results, positive or negative, should be submitted within 12 months, and no more than 18 months, after the drug is approved or the decision is made to discontinue the trial.
Clinical Trials Advisor
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.